



Rec'd CT/PTO

03 SEP 2004



INVESTOR IN PEOPLE

#2

**PRIORITY
DOCUMENT**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP1 080Q

08 MAY 2003

WIPO

PCT

PCT/GB 2003 / 0 0 0 9 2 4

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 20 March 2003

BEST AVAILABLE COPY

The
Patent
Office

THE PATENT OFFICE

6 MAR 2002

NEWPORT

04HAR02 E701027-11 C76921

101/7700 0.00 02/05/95

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference 100664

2. Patent application number
(The Patent Office will fill in this part)

0205175.3

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB
S-151 85 Sodertalje
Sweden

Patents ADP number (if you know it)

78 2244 8003

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

4. Title of the invention

CHEMICAL COMPOUNDS

5. Name of your agent (if you have one)

Rachel M. Tinsley

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Limited
Global Intellectual Property
Mereside, Alderley Park
Macclesfield
Cheshire SK10 4TG

Patents ADP number (if you know it)

6921 795002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 29

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

J. Marshall

Date

Authorised Signatory

05/03/2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Joanne M. Marshall - 01625 - 516485

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

CHEMICAL COMPOUNDS

The present invention relates to heterocyclic amide derivatives, pharmaceutically acceptable salts and *in vivo* hydrolysable esters thereof. These heterocyclic amide derivatives possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity and thus are potentially useful in methods of treatment of a warm-blooded animal such as man. The invention also relates to processes for the manufacture of said heterocyclic amide derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit glycogen phosphorylase activity in a warm-blooded animal such as man.

The liver is the major organ regulating glycaemia in the post-absorptive state. Additionally, although having a smaller role in the contribution to post-prandial blood glucose levels, the response of the liver to exogenous sources of plasma glucose is key to an ability to maintain euglycaemia. An increased hepatic glucose output (HGO) is considered to play an important role in maintaining the elevated fasting plasma glucose (FPG) levels seen in type 2 diabetics; particularly those with a FPG >140mg/dl (7.8mM). (Weyer et al, (1999), J Clin Invest 104: 787-794; Clore & Blackgard (1994), Diabetes 43: 256-262; De Fronzo, R. A., et al, (1992) Diabetes Care 15; 318 - 355; Reaven, G.M. (1995) Diabetologia 38; 3-13).

Since current oral, anti-diabetic therapies fail to bring FPG levels to within the normal, non-diabetic range and since raised FPG (and glycHbA1c) levels are risk factors for both macro- (Charles, M.A. et al (1996) Lancet 348, 1657-1658; Coutinho, M. et al (1999) Diabetes Care 22; 233-240; Shaw, J.E. et al (2000) Diabetes Care 23, 34-39) and micro-vascular disease (DCCT Research Group (1993) New. Eng. J. Med. 329; 977-986); the reduction and normalisation of elevated FPG levels remains a treatment goal in type 2 DM.

It has been estimated that, after an overnight fast, 74% of HGO was derived from glycogenolysis with the remainder derived from gluconeogenic precursors (Hellerstein et al (1997) Am J Physiol, 272: E163). Glycogen phosphorylase is a key enzyme in the generation by glycogenolysis of glucose-1-phosphate, and hence glucose in liver and also in other tissues such as muscle and neuronal tissue.


Liver glycogen phosphorylase activity is elevated in diabetic animal models including the db/db mouse and the fa/fa rat (Aiston S et al (2000). Diabetologia 43, 589-597).

Inhibition of hepatic glycogen phosphorylase with chloroindole inhibitors (CP91149 and CP320626) has been shown to reduce both glucagon stimulated glycogenolysis and glucose output in hepatocytes (Hoover et al (1998) J Med Chem 41, 2934-8; Martin et al (1998) PNAS 95, 1776-81). Additionally, plasma glucose concentration is reduced, in a dose related manner, db/db and ob/ob mice following treatment with these compounds.

Studies in conscious dogs with glucagon challenge in the absence and presence of another glycogen phosphorylase inhibitor, Bay K 3401, also show the potential utility of such agents where there is elevated circulating levels of glucagon, as in both Type 1 and Type 2 diabetes. In the presence of Bay K 3401, hepatic glucose output and arterial plasma glucose following a glucagon challenge were reduced significantly (Shiota et al, (1997), Am J Physiol, 273: E868).

The heterocyclic amides of the present invention possess glycogen phosphorylase inhibitory activity and accordingly are expected to be of use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia and obesity, particularly type 2 diabetes.

According to one aspect of the present invention there is provided a compound of formula (1):



(1)

wherein:


n is 0, 1 or 2;

m is 0, 1 or 2;

R¹ is independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-(C₁₋₄alkyl)₂carbamoyl, sulphamoyl, N-C₁₋₄alkylsulphamoyl, N,N-(C₁₋₄alkyl)₂sulphamoyl, sulfinio, sulfo, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋

$4\text{alkyl})_2\text{amino}$, hydroxy $\text{C}_{1-4}\text{alkyl}$, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy and R^1 is of the formula A or A':

$-(\text{CH}_2)_r$



(A)

$-\text{CH}_2\text{CH}(\text{OH})(\text{CH}_2)_r\text{CO}_2\text{H}$ (A')

wherein x is 0 or 1, r is 0, 1, 2 or 3 and s is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

R^4 is independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, $N\text{-C}_{1-4}\text{alkylcarbamoyl}$, $N,N\text{-(C}_{1-4}\text{alkyl})_2\text{carbamoyl}$, sulphamoyl, $N\text{-C}_{1-4}\text{alkylsulphamoyl}$, $N,N\text{-(C}_{1-4}\text{alkyl})_2\text{sulphamoyl}$, sulfinio, sulfo, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{2-4}\text{alkenyl}$, $\text{C}_{2-4}\text{alkynyl}$, $\text{C}_{1-4}\text{alkoxy}$, $\text{C}_{1-4}\text{alkanoyl}$, $\text{C}_{1-4}\text{alkanoyloxy}$, $N\text{-(C}_{1-4}\text{alkyl})\text{amino}$, $N,N\text{-(C}_{1-4}\text{alkyl})_2\text{amino}$, hydroxy $\text{C}_{1-4}\text{alkyl}$, fluoromethyl, difluoromethyl, trifluoromethyl and trifluoromethoxy.

B is phenyl or heterocyclyl;

R^{14} is selected from hydrogen, halo, $\text{C}_{1-4}\text{alkyl}$ (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), $\text{C}_{5-7}\text{cycloalkyl}$ (optionally substituted with 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), $\text{C}_{1-4}\text{alkoxy}$, cyano, cyano($\text{C}_{1-4}\text{alkyl}$), $-\text{COR}^3$, $(\text{R}^2)(\text{R}^3)\text{NCO}-$, and $(\text{R}^2)(\text{R}^3)\text{NSO}_2-$;

{ R^2 and R^3 are independently selected from $\text{C}_{1-4}\text{alkyl}$ (substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), $\text{C}_{5-7}\text{cycloalkyl}$ (optionally substituted with 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), cyano($\text{C}_{1-4}\text{alkyl}$), 4-butanolidyl, 5-pentanolidyl, tetrahydrothiopyranyl, 1-oxotetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, fluoromethylcarbonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl, $\text{C}_{1-4}\text{alkyl}$ (substituted by R^8), $-\text{OR}^8$ and R^8 ;

[wherein R^8 is independently selected from hydrogen, 2,2-dimethyl-1,3-dioxolan-4-yl, heterocyclyl (optionally substituted on ring carbon or ring nitrogen by 1 or 2 groups selected

- from hydrogen, nitro, halo, cyano, hydroxy and C₁₋₄alkyl), (heterocyclyl)C₁₋₄alkyl (wherein the heterocyclyl is optionally substituted on ring carbon or ring nitrogen by 1 or 2 groups selected from hydrogen, nitro, halo, cyano, hydroxy and C₁₋₄alkyl), aryl (optionally substituted by 1 or 2 groups selected from nitro, halo, cyano, hydroxy and C₁₋₄alkyl), C₁₋₄alkyl, C₂₋₄alkenyl, cyclo(C₃₋₈)alkyl, C₁₋₄alkoxy, cyano(C₁₋₄)alkyl, amino(C₁₋₄)alkyl (optionally substituted on nitrogen by 1 or 2 groups selected from hydrogen, C₁₋₄alkyl, hydroxy, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, aryl and aryl(C₁₋₄)alkyl), C₁₋₄alkylS(O)_c(C₁₋₄)alkyl (wherein c is 0, 1 or 2), -N(OH)CHO, -CH₂CH(CO₂R⁹)N(R⁹R¹⁰), -CH₂OR⁹, (R⁹)(R¹⁰)N-, -COOR⁹, -CH₂COOR⁹, -CH₂CONR⁹R¹⁰ and -CH₂CH(NR⁹R¹⁰)CO₂R⁹ (wherein u is 1; 2 or 3);
- (wherein R⁹ and R¹⁰ are independently selected from hydrogen, hydroxy, C₁₋₄alkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C₅₋₇cycloalkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C₂₋₄alkenyl, cyano(C₁₋₄)alkyl, 4-butanolidyl, 5-pentanolidyl, tetrahydrothiopyranyl, 1-oxotetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, 2,2-dimethyl-1,3-dioxolan-4-yl, aryl (optionally substituted by 1 or 2 substituents selected from hydrogen, nitro, halo, hydroxy and C₁₋₄alkyl) and C₁₋₄alkyl substituted by R¹³
- { wherein R¹³ is selected from hydroxy, C₁₋₄alkoxy, heterocyclyl, C₁₋₄alkanoyl, C₁₋₄alkylS(O)_d (wherein d is 0, 1 or 2), -N(OH)CHO, (R¹¹)(R¹²)NCO-, (R¹¹)(R¹²)NSO₂-, -COCH₂OR¹¹, (R¹¹)(R¹²)N-;
- [wherein R¹¹ and R¹² are independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, hydroxyC₁₋₄alkyl, C₁₋₄alkylS(O)_e (wherein e is 0, 1 or 2)]]; and
- R⁹ and R¹⁰ can together with the nitrogen to which they are attached form 4- to 6-membered ring where the ring is optionally substituted on carbon by 1 or 2 substituents selected from oxo, hydroxy, carboxy, halo, nitro, nitroso, cyano, isocyano, amino, N-C₁₋₄alkylamino, N,N-(C₁₋₄alkyl)₂amino, carbonyl, sulfo, C₁₋₄alkoxy, heterocyclyl, C₁₋₄alkanoyl, C₁₋₄alkylS(O)_f(C₁₋₄)alkyl (wherein f is 0, 1 or 2), -N(OH)CHO, (R¹¹)(R¹²)NCO-, (R¹¹)(R¹²)NSO₂-, -COCH₂OR¹¹, (R¹¹)(R¹²)N-;
- wherein R¹¹ and R¹² are as defined above]]];
- or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

In another aspect, the invention relates to compounds of formula (1) as hereinabove defined or to a pharmaceutically acceptable salt.

It is to be understood that, insofar as certain of the compounds of formula (1) defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses glycogen phosphorylase inhibition activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

Within the present invention it is to be understood that a compound of the formula (1) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which has glycogen phosphorylase inhibition activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein.

It is also to be understood that certain compounds of the formula (1) and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which have glycogen phosphorylase inhibition activity.

It is also to be understood that certain compounds of the formula (1) may exhibit polymorphism, and that the invention encompasses all such forms which possess glycogen phosphorylase inhibition activity.

The present invention relates to the compounds of formula (1) as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula (1) and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula (1) as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially—

hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. Suitable salts include hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates,

- 5 succinates, lactates and tartrates. In addition where the compounds of formula (1) are sufficiently acidic, pharmaceutically acceptable salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an ~~alkaline earth metal salt such as a calcium or magnesium salt~~, an ammonium salt or for
- 10 example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

An *in vivo* hydrolysable ester of a compound of formula (1) containing carboxy or hydroxy group is, for example a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid or alcohol.

- 15 Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example
- 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example
- 20 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

- Suitable pharmaceutically-acceptable esters for hydroxy include inorganic esters such as phosphate esters (including phosphoramidate cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the *in-vivo* hydrolysis of the ester breakdown to give
- 25 the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in-vivo* hydrolysable ester forming groups for hydroxy include C₁₋₁₀alkanoyl, for example acetyl; benzoyl; phenylacetyl; substituted benzoyl and phenylacetyl, C₁₋₁₀alkoxycarbonyl (to give alkyl carbonate esters), for example ethoxycarbonyl; di-(C₁₋₄)alkylcarbonyl and *N*-(di-(C₁₋₄)alkylaminoethyl)-*N*-(C₁₋₄)alkylcarbonyl (to give carbamates); di-(C₁₋₄)alkylaminoacetyl and carboxyacetyl.
- 30 Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, (C₁₋₄)alkylaminomethyl and di-((C₁₋₄)alkyl)aminomethyl, and morpholino or piperazino linked

from a ring nitrogen atom via a methylene linking group to the 3- or 4- position of the benzoyl ring. Other interesting in-vivo hydrolysable esters include, for example, $R^A C(O)O(C_{1-6})alkyl-CO-$, wherein R^A is for example, benzyloxy-(C_{1-4})alkyl, or phenyl). Suitable substituents on a phenyl group in such esters include, for example, 4-(C_{1-4})piperazino-(C_{1-4})alkyl, piperazino-
 5 (C₁₋₄)alkyl and morpholino-(C₁₋₄)alkyl.

In this specification the generic term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight chain version only and references to individual branched-chain alkyl groups such as *t*-butyl are specific for the branched chain version only. For example,
 10 "C₁₋₄alkyl" includes methyl, ethyl, propyl, isopropyl and *t*-butyl. An analogous convention applies to other generic terms, for example "C₂₋₄alkenyl" includes vinyl, allyl and 1-propenyl and "C₂₋₄alkynyl" includes ethynyl, 1-propynyl and 2-propynyl.

The term "hydroxyC₁₋₄alkyl" includes hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl and hydroxybutyl. The term "hydroxyethyl" includes 1-hydroxyethyl and 2-
 15 hydroxyethyl. The term "hydroxypropyl" includes 1-hydroxypropyl, 2-hydroxypropyl and 3-hydroxypropyl and an analogous convention applies to terms such as hydroxybutyl. The term "dihydroxyC₁₋₄alkyl" includes dihydroxymethyl, dihydroxyethyl, dihydroxypropyl, dihydroxyisopropyl and dihydroxybutyl. The term "dihydroxyethyl" includes 1,1-
 20 dihydroxyethyl 2,2-dihydroxyethyl and 1,2-dihydroxyethyl. An analogous convention applies to terms such as dihydroxypropyl, dihydroxyisopropyl and dihydroxybutyl.

The term "halo" refers to fluoro, chloro, bromo and iodo.

Examples of "C₁₋₄alkoxy" include methoxy, ethoxy, propoxy and isopropoxy.

Examples of "C₁₋₄alkanoyl" include formyl, acetyl and propionyl. Examples of

"C₁₋₄alkanoyloxy" are formyloxy, acetoxy and propionoxy. Examples of

25 "*N*-(C₁₋₄alkyl)amino" include methylamino and ethylamino. Examples of

"*N,N*-(C₁₋₄alkyl)₂amino" include *N,N*-(methyl)₂amino, *N,N*-(ethyl)₂amino and

N-ethyl-*N*-methylamino. Examples of "*N*-(C₁₋₄alkyl)carbamoyl" are methylcarbamoyl and

ethylcarbamoyl. Examples of "*N,N*-(C₁₋₄alkyl)₂carbamoyl" are *N,N*-(methyl)₂carbamoyl, *N,N*-

(ethyl)₂carbamoyl and *N*-methyl-*N*-ethylcarbamoyl. Examples of "*N*-(C₁₋₄alkyl)sulphamoyl"

30 are *N*-(methyl)sulphamoyl and *N*-(ethyl)sulphamoyl. Examples of

"*N,N*-(C₁₋₄alkyl)₂sulphamoyl" are *N,N*-(methyl)₂sulphamoyl, *N,N*-(ethyl)₂sulphamoyl and

N-(methyl)-*N*-(ethyl)sulphamoyl.

Examples of "cyano(C₁₋₄)alkyl" are cyanomethyl, cyanoethyl and cyanopropyl. Examples of "C₅₋₇cycloalkyl" are cyclopentyl, cyclohexyl and cycloheptyl. Examples of "C₃₋₈cycloalkyl" include "C₅₋₇cycloalkyl, cyclopropyl, cyclobutyl and cyclooctyl.

The term "aminoC₁₋₄alkyl" includes aminomethyl, aminoethyl, aminopropyl, aminoisopropyl and aminobutyl. The term "aminoethyl" includes 1-aminoethyl and 2-aminoethyl. The term "aminopropyl" includes 1-aminopropyl, 2-aminopropyl and 3-aminopropyl and an analogous convention applies to terms such as aminoisopropyl and aminobutyl.

Examples of "C₁₋₄alkylS(O)_c" (wherein c is 0 to 2)", "C₁₋₄alkylS(O)_d" (wherein d is 0 to 2)", "C₁₋₄alkylS(O)_e" (wherein e is 0 to 2)", and "C₁₋₄alkylS(O)_f" (wherein f is 0 to 2)" independently include methylthio, ethylthio, propylthio, methanesulphinyl, ethanesulphinyl, propanesulphinyl, mesyl, ethanesulphonyl, propanesulphonyl and isopropanesulphonyl.

Where optional substituents are chosen from "0, 1, 2 or 3" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. An analogous convention applies to substituents chose from "0, 1 or 2" groups and "1 or 2" groups.

"Heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 to 7 atoms of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxide(s). Examples and suitable values of the term "heterocyclyl" are morpholino, morpholinyl, piperidino, piperidinyl, pyridyl, pyranyl, pyrrolyl, imidazolyl, thiazolyl, thienyl, dioxolanyl, thiadiazolyl, piperazinyl, isothiazolidinyl, triazolyl, tetrazolyl, pyrrolidinyl, 2-oxazolidinonyl, 5-isoxazolonyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, 3-oxopyrazolin-5-yl, tetrahydropyranyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, 4-oxopyridyl, 2-oxopyrrolidyl, 4-oxothiazolidyl, furyl, thienyl, oxazolyl, and oxadiazolyl. Preferably "heterocyclyl" is morpholino, morpholinyl, piperidino, piperidyl, pyridyl, pyranyl, pyrrolyl, imidazolyl, thiazolyl, thienyl, thiadiazolyl, piperazinyl, isothiazolidinyl, 1,3,4-triazolyl, tetrazolyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, 4-oxopyridyl, 2-oxopyrrolidyl, 4-oxothiazolidyl, furyl, thienyl, oxazolyl and 1,2,4-oxadiazolyl.

More preferably "heterocyclyl" is oxazolyl, 1,2,4-oxadiazolyl, pyridyl, furyl, thienyl, morpholine, pyrazinyl and piperazinyl.

Examples of "(heterocyclyl)C₁₋₄alkyl" are morpholinomethyl, morpholinethyl, morpholinylmethyl, morpholinylethyl, piperidinomethyl, piperidinoethyl, piperidylmethyl, piperidylethyl, imidazolylmethyl, imidazolylethyl, oxazolylmethyl, oxazolylethyl, 1,2,4-oxadiazolylmethyl, 1,2,4-oxadiazolylethyl, pyridylmethyl, pyridylethyl, furylmethyl, furylethyl, (thienyl)methyl, (thienyl)ethyl, pyrazinylmethyl, pyrazinylethyl, piperazinylmethyl and piperazinylethyl.

~~Examples of "aryl" are phenyl and naphthyl.~~

Examples of "aryl(C₁₋₄)alkyl" are benzyl, 2-phenylethyl, naphthylmethyl and naphthylethyl.


Preferred values of B, R¹, R⁴, R¹⁴, m and n are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

In one aspect of the present invention there is provided a compound of formula (1) as depicted above.

In one aspect of the invention n is 0 or 1.

Preferably n is 1.

In another aspect of the present invention R¹ is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl and R¹ is of the formula A or A':



(A)



wherein x is 0 or 1, r is 0, 1, 2 or 3 and s is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

Preferably R¹ is hydrogen or halo.

More preferably R¹ is hydrogen, chloro or fluoro.

In one aspect of the invention B is phenyl.

In another aspect of the invention B is heterocyclyl.

Preferably B is selected from phenyl, pyridyl, pyrimidinyl, pyrrolyl, thienyl, furyl,
5 oxazole, isoxazole and oxadiazole.

In one aspect of the invention R^{14} is selected from hydrogen, halo, C_{1-4} alkyl
(optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy
groups they are not substituents on the same carbon), C_{5-7} cycloalkyl (optionally substituted
10 with 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not
substituents on the same carbon), C_{1-4} alkoxy, cyano, cyano(C_{1-4})alkyl, $-COR^3$, $(R^2)(R^3)NCO-$,
and $(R^2)(R^3)NSO_2-$;

{ wherein R^2 and R^3 are independently selected from C_{1-4} alkyl (substituted by 1 or 2
hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the
15 same carbon), C_{5-7} cycloalkyl (optionally substituted with 1 or 2 hydroxy groups provided that
when there are 2 hydroxy groups they are not substituents on the same carbon), cyano(C_{1-4})
alkyl, fluoromethylcarbonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl, C_{1-4} alkyl
(substituted by R^8), $-OR^8$ and R^8 ;

[wherein R^8 is independently selected from hydrogen, furyl (optionally substituted on
20 carbon by 1 or 2 nitro groups), thienyl (optionally substituted on carbon by 1 or 2 nitro
groups), morpholino, furyl(C_{1-4})alkyl (wherein furyl is optionally substituted on carbon by 1
or 2 nitro groups), thienyl(C_{1-4})alkyl (wherein thienyl is optionally substituted on carbon by 1
or 2 nitro groups), 1,2,4-oxadiazolyl, tetrazolyl, ~~imidazolyl~~, pyrrolidinyl, piperidyl,
tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, phenyl (optionally
25 substituted by 1 or 2 groups selected from nitro, halo, cyano, hydroxy and C_{1-4} alkyl),
pyrazinyl, 4-methylpiperazino, piperazinyl, C_{1-4} alkyl, C_{2-4} alkenyl, cyclo(C_{3-8})alkyl, C_{1-4}
alkoxy, cyano(C_{1-4})alkyl, amino(C_{1-4})alkyl (optionally substituted on nitrogen by 1 or 2
groups selected from hydrogen, C_{1-4} alkyl, hydroxy, hydroxy(C_{1-4})alkyl, dihydroxy(C_{1-4})alkyl,
aryl and aryl(C_{1-4})alkyl), $C_{1-4}alkylS(O)_c(C_{1-4})alkyl$ (wherein c is 0, 1 or 2), -
30 $CH_2CH(CO_2R^9)N(R^9R^{10})$, $-CH_2OR^9$, $(R^9)(R^{10})N-$, $-COOR^9$ and $-CH_2COOR^9$, -
 $CH_2CONR^9R^{10}$, $-CH_2CH_2CH(NR^9R^{10})CO_2R^9$

(wherein R^9 and R^{10} are independently selected from hydrogen, C_{1-4} alkyl (optionally
substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are

not substituents on the same carbon), C₅₋₇cycloalkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C₂₋₄alkenyl, cyano(C₁₋₄)alkyl, phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, hydroxy and cyano) and C₁₋₄alkyl substituted by R¹³;

5 { wherein R¹³ is selected from C₁₋₄alkoxy, furyl (optionally substituted on carbon by 1 or 2 nitro groups), thienyl (optionally substituted on carbon by 1 or 2 nitro groups), morpholino, furyl(C₁₋₄)alkyl (wherein furyl is optionally substituted on carbon by 1 or 2 nitro groups), thienyl(C₁₋₄)alkyl (wherein thienyl is optionally substituted on carbon by 1 or 2 nitro groups), 1,2,4-oxadiazolyl, tetrazolyl, imidazolyl, pyrrolidinyl, piperidyl, tetrahydrofuryl; 10 tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, cyano, hydroxy and C₁₋₄alkyl), pyrazinyl, piperazinyl, C₁₋₄alkylS(O)_d(C₁₋₄)alkyl (wherein d is 0, 1 or 2);

[wherein R¹¹ is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, hydroxyC₁₋₄alkyl, C₁₋₄alkylS(O)_e (wherein e is 0, 1 or 2)]; and

15 R⁹ and R¹⁰ can together with the nitrogen to which they are attached form 4- to 6-membered ring where the ring is optionally substituted on carbon by 1 or 2 substituents selected from oxo, hydroxy, carboxy, halo, nitro, nitroso, cyano, isocyano, amino, N-C₁₋₄alkylamino, N,N-(C₁₋₄)₂alkylamino, carbonyl, sulfo, C₁₋₄alkoxy, heterocyclyl, C₁₋₄alkanoyl, and C₁₋₄alkylS(O)_f(C₁₋₄)alkyl (wherein f is 0, 1 or 2))];

20

In a further aspect of the invention R¹⁴ is selected from hydrogen, -COR³, (R²)(R³)NCO-, and (R²)(R³)NSO₂-;

{ wherein R² and R³ are independently selected from C₁₋₄alkyl (substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the 25 same carbon), fluoromethylcarbonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl, C₁₋₄alkyl (substituted by R⁸), -OR⁸ and R⁸;

[wherein R⁸ is independently selected from hydrogen, furyl (optionally substituted on carbon by 1 or 2 nitro groups), thienyl (optionally substituted on carbon by 1 or 2 nitro groups), morpholino, furyl(C₁₋₄)alkyl (wherein furyl is optionally substituted on carbon by 1 or 2 nitro groups), thienyl(C₁₋₄)alkyl (wherein thienyl is optionally substituted on carbon by 1 30 or 2 nitro groups), phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, cyano and hydroxy), C₂₋₄alkenyl, cyclo(C₃₋₈)alkyl, cyano(C₁₋₄)alkyl, amino(C₁₋₄)alkyl (optionally substituted on nitrogen by 1 or 2 groups selected from hydrogen, C₁₋₄alkyl,

hydroxy, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, aryl and aryl(C₁₋₄)alkyl), C₁₋₄alkylS(O)_c(C₁₋₄)alkyl (wherein c is 0, 1 or 2), -CH₂CH(CO₂R⁹)N(R⁹R¹⁰), -CH₂OR⁹, (R⁹)(R¹⁰)N-, -COOR⁹, -CH₂COOR⁹, -CH₂CONR⁹R¹⁰, and -CH₂CH₂CH(NR⁹R¹⁰)CO₂R⁹;

(wherein R⁹ and R¹⁰ are independently selected from hydrogen, C₁₋₄alkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C₂₋₄alkenyl, cyano(C₁₋₄)alkyl and phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, hydroxy and cyano))].

In another aspect of the invention R¹⁴ is selected from hydrogen, -COR³,

(R²)(R³)NCO-, and (R²)(R³)NSO₂-;

{ wherein R² and R³ are independently selected from C₁₋₄alkyl (substituted by R⁸), -OR⁸ and R⁸;

[wherein R⁸ is independently selected from hydrogen, furyl (optionally substituted on carbon by 1 or 2 nitro groups), thienyl (optionally substituted on carbon by 1 or 2 nitro groups), morpholino, furyl(C₁₋₄)alkyl (wherein furyl is optionally substituted on carbon by 1 or 2 nitro groups), thienyl(C₁₋₄)alkyl (wherein thienyl is optionally substituted on carbon by 1 or 2 nitro groups), phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, cyano and hydroxy), C₂₋₄alkenyl, cyano(C₁₋₄)alkyl, cyclo(C₃₋₈)alkyl, amino(C₁₋₄)alkyl (optionally substituted on nitrogen by 1 or 2 groups selected from hydrogen, C₁₋₄alkyl, hydroxy, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, aryl and aryl(C₁₋₄)alkyl) and C₁₋₄alkylS(O)_c(C₁₋₄)alkyl (wherein c is 0, 1 or 2))].

In another aspect of the invention R¹⁴ is selected from hydrogen, halo, cyano, C₁₋₄alkoxy, C₁₋₄alkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon) and cyanoC₁₋₄alkyl.

In another aspect of the invention R¹⁴ is selected from hydrogen, -COR³, (R²)(R³)NCO-, and (R²)(R³)NSO₂-;

{ wherein R² is selected from hydrogen or C₁₋₄alkyl and R³ is selected from hydrogen, methyl, hydroxyethyl, hydroxypropyl, 1,3-dihydroxyprop-2-yl, 3-hydroxy-2-hydroxymethylpropyl, 2,3-dihydroxypropyl, cyanomethyl, cyanoethyl, cyanopropyl, cyanomethylcarbonyl, cyanoethylcarbonyl, cyanopropylcarbonyl, carbamoyl, trifluoromethylcarbonyl, carboxymethanoyl, 4-amino-4-carboxybutanoyl, carboxyethyl,

- formyl, acetyl, propanoyl, methanesulfinyl, methanesulfonyl, morpholinomethylcarbonyl, phenylcarbonyl, furylcarbonyl, thienylcarbonyl, nitrofurylcarbonyl, pyrazinylcarbonyl, cyclopropylcarbonyl, morpholinocarbonyl, methylmercaptoethyl, *N,N*-(methyl)₂carbamoyl, 4-methylpiperazinocarbonyl, thienylsulfonyl, *N*-ethylcarbamoyl, *N*-allylcarbamoyl, *N*-dinitrophenylcarbamoyl, pyridinylcarbonyl, cyanophenylcarbonyl, hydroxyphenylcarbonyl, acryloyl, 2-amino-2-carboxyethylcarbonyl, 2-(tert-butoxycarbonyl)-2-(tert-butoxycarbonylamino)ethylcarbonyl, 2-(tert-butoxycarbonyl)ethylcarbonyl, aminobutanoyl, aminopropanoyl, aminoacetyl, *N*-methylaminoacetyl, 3-amino-3-carboxypropanoyl, chloroacetyl, hydroxyacetyl, ~~*N*-methyl-*N*-hydroxyethylaminoacetyl, *N*-benzyl-*N*-hydroxyethylaminoacetyl, *N*-methyl-*N*-hydroxyethylaminoacetyl, *N*-benzyl-*N*-hydroxyethylaminoacetyl~~, hydroxyethylaminoacetyl, *N*-(2,3-dihydroxypropyl)-*N*-methylaminoacetyl, hydroxypiperidinoaminoacetyl, hydroxypyrrolidinylaminoacetyl, *N,N*-bis(hydroxyethyl)aminoacetyl.

In one aspect of the present invention *m* is 1 or 2.

- 15 In another aspect of the invention *m* is 1.

In one aspect of the present invention *R*⁴ is selected from hydrogen, halo, cyano, hydroxy, fluoromethyl, difluoromethyl and trifluoromethyl.

In another aspect of the invention *R*⁴ is hydrogen or halo.

- 20 Preferably *R*⁴ is selected from hydrogen, chloro or bromo.


More preferably *R*⁴ is chloro.

A preferred class of compound is of the formula (1) wherein,

- 25 *n* is 1 or 2;

*R*¹ is independently selected from hydrogen, halo, cyano, nitro, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl and *R*¹ is of the formula A or A':

—(CH₂)_r



(A)

—CH₂CH(OH)(CH₂)_rCO₂H (A')

wherein x is 0 or 1, r is 0, 1, 2 or 3 and s is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

B is heterocyclyl;

5

R^{14} is selected from is selected from hydrogen, C_{1-4} alkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C_{5-7} cycloalkyl (optionally substituted with 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), cyano(C_{1-4})alkyl, $-COR^3$, $(R^2)(R^3)NCO-$, and $(R^2)(R^3)NSO_2-$;

{ wherein R^2 and R^3 are independently selected from C_{1-4} alkyl (substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C_{5-7} cycloalkyl (optionally substituted with 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), cyano(C_{1-4})alkyl, fluoromethylcarbonyl, difluoromethylcarbonyl, trifluoromethylcarbonyl, C_{1-4} alkyl (substituted by R^8), $-OR^8$ and R^8 ;

[wherein R^8 is independently selected from hydrogen, furyl (optionally substituted on carbon by 1 or 2 nitro groups), thienyl (optionally substituted on carbon by 1 or 2 nitro groups), morpholino, furyl(C_{1-4})alkyl (wherein furyl is optionally substituted on carbon by 1 or 2 nitro groups), thienyl(C_{1-4})alkyl (wherein thienyl is optionally substituted on carbon by 1 or 2 nitro groups), 1,2,4-oxadiazolyl, tetrazolyl, imidazolyl, pyrrolidinyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, morpholino, pyridyl, phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, cyano, hydroxy and C_{1-4} alkyl), pyrazinyl, piperazinyl, 4-methylpiperazino, C_{1-4} alkyl, C_{2-4} alkenyl, cyclo(C_{3-8})alkyl, C_{1-4} alkoxy, cyano(C_{1-4})alkyl, amino(C_{1-4})alkyl (optionally substituted on nitrogen by 1 or 2 groups selected from hydrogen, C_{1-4} alkyl, hydroxy, hydroxy(C_{1-4})alkyl, dihydroxy(C_{1-4})alkyl, aryl and aryl(C_{1-4})alkyl), $C_{1-4}alkylS^{(c)}(C_{1-4})alkyl$ (wherein c is 0, 1 or 2), $-CH_2CH(CO_2R^9)N(R^9R^{10})$, $-CH_2OR^9$, $(R^9)(R^{10})N-$, $-COOR^9$, $-CH_2COOR^9$, $-CH_2CONR^9R^{10}$, and $-CH_2CH_2CH(NR^9R^{10})CO_2R^9$;

(wherein R^9 and R^{10} are independently selected from hydrogen, C_{1-4} alkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C_{5-7} cycloalkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same

carbon), C_{2-4} alkenyl, cyano(C_{1-4})alkyl, phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, hydroxy and cyano) and C_{1-4} alkyl substituted by R^{13} ;

{ wherein R^{13} is selected from C_{1-4} alkoxy, furyl (optionally substituted on carbon by 1 or 2 nitro groups), thienyl (optionally substituted on carbon by 1 or 2 nitro groups),

5 morpholino, furyl(C_{1-4})alkyl (wherein furyl is optionally substituted on carbon by 1 or 2 nitro groups), thienyl(C_{1-4})alkyl (wherein thienyl is optionally substituted on carbon by 1 or 2 nitro groups), 1,2,4-oxadiazolyl, tetrazolyl, imidazolyl, pyrrolidinyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, cyano, hydroxy and C_{1-4} alkyl), pyrazinyl, piperazinyl, 10 C_{1-4} alkylS(O)_d(C_{1-4})alkyl (wherein d is 0, 1 or 2)); and

R^9 and R^{10} can together with the nitrogen to which they are attached form 4- to 6-membered ring where the ring is optionally substituted on carbon by 1 or 2 substituents selected from oxo, hydroxy, carboxy, halo, nitro, nitroso, cyano, isocyano, amino, N - C_{1-4} alkylamino, N,N -(C_{1-4})₂alkylamino, carbonyl, sulfo, C_{1-4} alkoxy, heterocyclyl, C_{1-4} alkanoyl, 15 and C_{1-4} alkylS(O)_f(C_{1-4})alkyl (wherein f is 0, 1 or 2))];

m is 1 or 2;

R^4 is hydrogen or halo;

20 or a pharmaceutically acceptable salt thereof.


Another preferred class of compound is of the formula (1) wherein:

n is 1 or 2;

25

R^1 is independently selected from hydrogen, halo, nitro, hydroxy, C_{1-4} alkyl and R^1 is of the formula A or A':

$-(CH_2)_r$



(A)

$-CH_2CH(OH)(CH_2)_uCO_2H$ (A')

wherein x is 0 or 1, r is 0, 1, 2 or 3 and s is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

B is heterocyclyl;

5

R^{14} is selected from is selected from hydrogen, C_{1-4} alkyl, cyano(C_{1-4})alkyl, $-COR^3$, $(R^2)(R^3)NCO-$, and $(R^2)(R^3)NSO_2-$;

10 { wherein R^2 and R^3 are independently selected from C_{1-4} alkyl (substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), cyano(C_{1-4})alkyl, trifluoromethylcarbonyl, C_{1-4} alkyl (substituted by R^8), $-OR^8$ and R^8 ;

15 [wherein R^8 is independently selected from hydrogen, furyl (optionally substituted on carbon by 1 or 2 nitro groups), thienyl (optionally substituted on carbon by 1 or 2 nitro groups), morpholino, furyl(C_{1-4})alkyl (wherein furyl is optionally substituted on carbon by 1 or 2 nitro groups), thienyl(C_{1-4})alkyl (wherein thienyl is optionally substituted on carbon by 1 or 2 nitro groups), 1,2,4-oxadiazolyl, tetrazolyl, imidazolyl, pyrrolidinyl, piperidyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, cyano, hydroxy and C_{1-4} alkyl), pyrazinyl, piperazinyl, 4-methylpiperazino, C_{1-4} alkyl, C_{2-4} alkenyl, cyclo(C_{3-8})alkyl, C_{1-4} alkoxy, cyano(C_{1-4})alkyl, amino(C_{1-4})alkyl (optionally substituted on nitrogen by 1 or 2 groups selected from hydrogen, C_{1-4} alkyl, hydroxy, hydroxy(C_{1-4})alkyl, dihydroxy(C_{1-4})alkyl, aryl and aryl(C_{1-4})alkyl), $C_{1-4}alkylS(O)_e(C_{1-4})alkyl$ (wherein e is 0, 1 or 2), -
20 $CH_2CH(CO_2R^9)N(R^9R^{10})$, $-CH_2OR^9$, $(R^9)(R^{10})N$, $-COOR^9$, $-CH_2COOR^9$, $-CH_2CONR^9R^{10}$, and $-CH_2CH_2CH(NR^9R^{10})CO_2R^9$;

25 (wherein R^9 and R^{10} are independently selected from hydrogen, C_{1-4} alkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C_{5-7} cycloalkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C_{2-4} alkenyl, cyano(C_{1-4})alkyl and phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, hydroxy and cyano); and
30

R^9 and R^{10} can together with the nitrogen to which they are attached form 4- to 6-membered ring where the ring is optionally substituted on carbon by 1 or 2 substituents selected from oxo, hydroxy, carboxy, halo, nitro, nitroso, cyano, isocyano, amino, $N-C_1-$

alkylamino, *N,N*-(C₁₋₄)₂alkylamino, carbonyl, sulfo, C₁₋₄alkoxy, heterocyclyl, C₁₋₄alkanoyl, and C₁₋₄alkylS(O)_f(C₁₋₄)alkyl (wherein *f* is 0, 1 or 2))];

m is 1 or 2;

5

R⁴ is hydrogen or halo;

or a pharmaceutically acceptable salt thereof.


Another preferred class of compound is of the formula (1) wherein:

10

n is 1 or 2;

R¹ is independently selected from hydrogen, halo, nitro, hydroxy, C₁₋₄alkyl and R¹ is of the formula A or A':

-(CH₂)_r



(A)

-CH₂CH(OH)(CH₂)_sCO₂H (A')

15

wherein *x* is 0 or 1, *r* is 0, 1, 2 or 3 and *s* is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

B is heterocyclyl;

20

R¹⁴ is selected from C₁₋₄alkyl, cyano(C₁₋₄)alkyl, -COR³, (R²)(R³)NCO-, and (R²)(R³)NSO₂-;

{ wherein R² and R³ are independently selected from C₁₋₄alkyl, C₁₋₄alkyl (substituted by R⁸), -OR⁸ and R⁸;

25

[wherein R⁸ is independently selected from hydrogen, furyl (optionally substituted on carbon by 1 or 2 nitro groups), thienyl (optionally substituted on carbon by 1 or 2 nitro groups), morpholino, furyl(C₁₋₄)alkyl (wherein furyl is optionally substituted on carbon by 1 or 2 nitro groups), thienyl(C₁₋₄)alkyl (wherein thienyl is optionally substituted on carbon by 1 or 2 nitro groups), 1,2,4-oxadiazolyl, tetrazolyl, imidazolyl, pyrrolidinyl, piperidyl,

tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, cyano, hydroxy and C₁₋₄alkyl), pyrazinyl, piperazinyl, C₁₋₄alkyl, C₂₋₄alkenyl, cyclo(C₃₋₈)alkyl, C₁₋₄alkoxy, cyano(C₁₋₄)alkyl, amino(C₁₋₄)alkyl (optionally substituted on nitrogen by 1 or 2 groups selected from hydrogen, C₁₋₄alkyl, hydroxy, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, aryl and aryl(C₁₋₄)alkyl), C₁₋₄alkylS(O)_c(C₁₋₄)alkyl (wherein c is 0, 1 or 2), -CH₂CH(CO₂R⁹)N(R⁹R¹⁰), -CH₂OR⁹, (R⁹)(R¹⁰)N-, -COOR⁹, -CH₂COOR⁹, -CH₂CONR⁹R¹⁰, and -CH₂CH₂CH(NR⁹R¹⁰)CO₂R⁹; (wherein R⁹ and R¹⁰ are independently C₁₋₄alkenyl or phenyl (optionally substituted by nitro, halo or cyano))]]}

m is 1;

R⁴ is chloro;


or a pharmaceutically acceptable salt thereof.

Another preferred class of compound is of the formula (1) wherein:

n is 1 or 2;

R¹ is independently selected from hydrogen, halo, nitro, hydroxy, C₁₋₄alkyl and R¹ is of the formula A or A':

-(CH₂)_r



(A)

-CH₂CH(OH)(CH₂)_nCO₂H (A')

wherein x is 0 or 1, r is 0, 1, 2 or 3 and s is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

B is heterocyclyl;

R^{14} is selected from hydrogen, halo, cyano, C_{1-4} alkoxy, C_{1-4} alkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon) and cyano C_{1-4} alkyl.

5 m is 1;

R^4 is chloro;


or a pharmaceutically acceptable salt thereof.

10 Another preferred class of compound is of the formula (1) wherein:

n is 1 or 2;

15 R^1 is independently selected from hydrogen, halo, nitro, hydroxy, C_{1-4} alkyl and R^1 is of the formula A or A':

$-(CH_2)_r$



(A)

$-CH_2CH(OH)(CH_2)_nCO_2H$ (A')

wherein x is 0 or 1, r is 0, 1, 2 or 3 and s is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

20 B is phenyl;

R^{14} is selected from is selected from C_{1-4} alkyl, cyano(C_{1-4})alkyl, $-COR^3$, $(R^2)(R^3)NCO-$, and $(R^2)(R^3)NSO_2-$;

25 {wherein R^2 and R^3 are independently selected from C_{1-4} alkyl, C_{1-4} alkyl (substituted by R^8), $-OR^8$ and R^8 ;

[wherein R^8 is independently selected from hydrogen, heterocyclyl (optionally substituted on carbon or nitrogen by 1 or 2 groups selected from nitro, halo, hydroxy, cyano and C_{1-4} alkyl), (heterocyclyl)(C_{1-4})alkyl (optionally substituted on carbon or nitrogen by 1 or 2 groups selected from nitro, halo, hydroxy, cyano and C_{1-4} alkyl), aryl (optionally substituted by

1 or 2 groups selected from nitro, halo, cyano, hydroxy and C₁₋₄alkyl), C₁₋₄alkyl, C₂₋₄alkenyl, cyclo(C₃₋₈)alkyl, C₁₋₄alkoxy, cyano(C₁₋₄)alkyl, amino(C₁₋₄)alkyl (optionally substituted on nitrogen by 1 or 2 groups selected from hydrogen, C₁₋₄alkyl, hydroxy, hydroxy(C₁₋₄)alkyl, dihydroxy(C₁₋₄)alkyl, aryl and aryl(C₁₋₄)alkyl), C₁₋₄alkylS(O)_c(C₁₋₄)alkyl (wherein c is 0, 1 or 2), -(CH₂)_uCH(CO₂R⁹)N(R⁹R¹⁰) (wherein u is 0, 1 or 2), -CH₂OR⁹, (R⁹)(R¹⁰)N-, -COOR⁹ and -CH₂COOR⁹, -CH₂CONR⁹R¹⁰, -CH₂CH₂CH(NR⁹R¹⁰)CO₂R⁹;

(wherein R⁹ and R¹⁰ are independently selected from hydrogen, C₁₋₄alkyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C₂₋₄alkenyl (optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon), C₂₋₄alkenyl, cyano(C₁₋₄)alkyl, and phenyl (optionally substituted by 1 or 2 groups selected from nitro, halo, hydroxy and cyano))];

m is 1;


R⁴ is chloro;

or a pharmaceutically acceptable salt thereof.

In another aspect of the invention, preferred compounds of the invention are any one of:
methyl (S)-5-{1-[(5-chloro-1H-indol-2-ylcarbonyl)amino]-2-phenylethyl}oxazole-4-carboxylate;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.


Another aspect of the present invention provides a process for preparing a compound of formula (1) or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof which process (wherein B, R¹, R⁴, R¹⁴ m and n are, unless otherwise specified, as defined in formula (1)) comprises of:

a) reacting an acid of the formula (2):



(2)

or an activated derivative thereof; with an amine of formula (3):



(3)

5 and thereafter if necessary:

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

Specific reaction conditions for the above reaction are as follows.

10 *Process a)* Acids of formula (2) and amines of formula (3) may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole, 1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide hydrochloride and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as 1-
 15 hydroxybenzotriazole, dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, di-isopropylethylamine, pyridine, or 2,6-dialkylpyridines such as 2,6-lutidine or 2,6-di-*tert*-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of -40 to 40°C.

20 Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of
 25 -40 to 40°C.

The acids of formula (2) are commercially available or they are known compounds or they are prepared by processes known in the art.

Processes for the preparation of compounds of formula (3) often involve heterocyclic ring formation. Compounds of formula (3) may therefore be prepared by processes known in the art and in particular with reference to Alan R. Katritzky, Comprehensive Heterocyclic Chemistry, Pergamon Press. Processes for the preparation of compounds of formula (3) may also be found in Tett. Letts., Vol23, no2, p 235.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogen group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection

conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate): ~~A suitable alternative protecting group for a~~ primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

Certain intermediates in the preparation of a compound of the formula (1) are novel and form another aspect of the invention.

As stated hereinbefore the compounds defined in the present invention possesses glycogen phosphorylase inhibitory activity. This property may be assessed, for example, using the procedure set out below.

Assay

The activity of the compounds is determined by measuring the inhibitory effect of the compounds in the direction of glycogen synthesis, the conversion of glucose-1-phosphate into glycogen with the release of inorganic phosphate, as described in EP 0 846 464 A2. The reactions were in 96well microplate format in a volume of 100 μ l. The change in optical density due to inorganic phosphate formation was measured at 620nm in a Labsystems iEMS Reader MF by the general method of (Nordlie R.C and Arion W.J, Methods of Enzymology, 1966, 619-625). The reaction is in 50mM HEPES, 2.5mM MgCl₂, 2.25mM ethylene glycol-bis(b-amin \ddot{o} ethyl ether) *N,N,N',N'*-tetraacetic acid, 100mM KCl, 2mM D-(+)-glucose pH7.2, containing 0.5mM dithiothreitol, the assay buffer solution, with 0.1mg type III glycogen, 0.15ug glycogen phosphorylase α (GP α) from rabbit muscle and 0.5mM glucose-1-phosphate. GP α is pre-incubated in the assay buffer solution with the type III glycogen at 2.5 mg ml⁻¹ for 30 minutes. 40 μ l of the enzyme solution is added to 25 μ l assay buffer solution and the reaction started with the addition of 25 μ l 2mM glucose-1-phosphate. Compounds to be tested are prepared in 10 μ l 10% DMSO in assay buffer solution, with final concentration of 1% DMSO in the assay. The non-inhibited activity of GP α is measured in the presence of 10 μ l 10% DMSO in assay buffer solution and maximum inhibition measured in the presence of 30 μ M CP320626 (Hoover et al (1998) J Med Chem 41, 2934-8; Martin et al (1998) PNAS 95, 1776-81). The reaction is stopped after 30min with the addition of 50 μ l acidic ammonium molybdate solution, 12ug ml⁻¹ in 3.48% H₂SO₄ with 1% sodium lauryl sulphate and 10ug ml⁻¹ ascorbic acid. After 30 minutes at room temperature the absorbency at 620nm is measured.

The assay is performed with a range of test concentrations of inhibitor to determine an IC₅₀, a concentration predicted to inhibit the enzyme reaction by 50%.

Activity is calculated as follows:-

% inhibition = (1 - (compound OD₆₂₀ - fully inhibited OD₆₂₀) / (non-inhibited rate OD₆₂₀ - fully inhibited OD₆₂₀)) * 100.

OD₆₂₀ = optical density at 620nm.

Typical IC₅₀ values for compounds of the invention when tested in the above assay are in the range 100 μ M to 1nM. For example IC₅₀ of example 1 is 2 μ M.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in association

with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical
5 administration as an ointment or cream or for rectal administration as a suppository.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compound of formula (1) will normally be administered to a warm-blooded animal at a unit dose within the range ~~5-5000 mg per square meter body area of the animal,~~
10 i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum
15 dosage may be determined by the practitioner who is treating any particular patient.

According to a further aspect of the present invention there is provided a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use in a method of treatment of a warm-blooded animal such as man by therapy.

20 According to an additional aspect of the invention there is provided a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament.

According to an additional aspect of the invention there is provided a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as
25 defined hereinbefore, for use as a medicament in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.

According to this another aspect of the invention there is provided the use of a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable
30 ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal such as man.

According to this another aspect of the invention there is provided the use of a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of type 2 diabetes in a warm-blooded animal such as man.

5 According to a further feature of this aspect of the invention there is provided a method of producing a glycogen phosphorylase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

10 According to this further feature of this aspect of the invention there is provided a method of treating type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

15 According to this further feature of this aspect of the invention there is provided a method of treating type 2 diabetes in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

20 As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.

25 In addition to their use in therapeutic medicine, the compounds of formula (1) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

Examples


The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- 5 (i) temperatures are given in degrees Celsius ($^{\circ}\text{C}$); operations were carried out at room or ambient temperature, that is, at a temperature in the range of $18\text{--}25^{\circ}\text{C}$ and under an atmosphere of an inert gas such as argon;
- (ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure ($600\text{--}4000$ Pascals; $4.5\text{--}30$ mmHg) with a bath temperature of up to 60°C ;
- 10 (iii) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
- (iv) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
- 15 (v) where given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide ($\text{DMSO-}d_6$) as solvent unless otherwise indicated, other solvents (where indicated in the text) include deuterated chloroform CDCl_3 ;
- 20 (vi) chemical symbols have their usual meanings; SI units and symbols are used;
- (vii) solvent ratios are given in volume : volume (v/v) terms;
- (viii) The following abbreviations are used:

	EtOAc	ethyl acetate;
	DCM	dichloromethane;
25	HOBT	1-hydroxybenzotriazole;
	DIPEA	di-isopropylethylamine;
	EDAC	1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide hydrochloride;

Example 1

Methyl (S)-5-{1-[5-chloro-1H-indol-2-ylcarbonyl]amino}-2-phenylethyl}oxazole-4-carboxylate




5 2-Carboxy-5-chloro-indole (146mg, 0.75mmol) was dissolved in DCM (5ml) containing HOBT (126mg, 0.93mmol), DIPEA (290mg, 2.25mmol) and methyl (S)-5-(1-amino-2-phenylethyl)oxazole-4-carboxylate trifluoroacetate (**Method 1**; 360mg, 0.75mmol). EDAC (178mg, 0.93mmol) was added and the mixture stirred at ambient temperature for 4 hours. The reaction mixture was diluted with ethyl acetate (30ml), washed with dilute citric acid, water and brine, dried over magnesium sulphate and concentrated. The crude material
10 was purified by trituration with diethyl ether to give the title compound as a white solid. (227mg, 65%)
NMR 3.1-3.2(1H,m); 3.25-3.3(1H,m); 3.8(3H,s); 5.9-6.0(1H,m); 7.1-7.3(7H,m); 7.4(1H,d); 7.75(1H,d); 8.46(1H,s); 9.1(1H,d); 11.68(1H,bs)

15

Method 1

Methyl (S)-5-(1-amino-2-phenylethyl)oxazole-4-carboxylate trifluoroacetate



20 Methyl (S)-5-[1-(*tert*-butoxycarbonylamino)2-phenylethyl]oxazole-4-carboxylate, (Tett. Lett., 1982, 23, 235; 417mg) was dissolved in trifluoroacetic acid (3ml) and stood at ambient temperature for 1 hour and concentrated to give an oil. Trituration with diethyl ether gave the title compound as a white solid. (281mg).

NMR 3.1-3.25(1H,m); 3.3-3.4(1H,m); 3.7(3H,s); 5.2-5.3(1H,m); 7.05(2H,d); 7.2-7.3(3H,m);
8.7(1H,s); 8.75-8.85(3H,bs)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.